25. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie (GAA)
Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie
22.11. - 23.11.2018, Bonn/Bad Godesberg
Abstracts
Meeting Abstract
(18gaa01)
[Volltext]
„QT-Life“: Prevention of adverse drug effects, in particular torsade de pointes-events, by pharmacy-based basic data collection
Bodmer T, Augustin M, Froese P, Volmer T[Volltext]
Meeting Abstract
(18gaa02)
[Volltext]
Use of proton pump inhibitors at the University hospital Jena
Farker K, Hildwein D, Kummer S, Hartmann M[Volltext]
Meeting Abstract
(18gaa03)
[Volltext]
Epidemiology, outcomes and treatment patterns among patients with coronary artery disease and/or peripheral artery disease treated in routine clinical practice in Germany
Beier D, Galetzka W, Hickstein L, Meinhardt M, Häckl D, Schmedt N[Volltext]
Meeting Abstract
(18gaa04)
[Volltext]
Pharmaceutical advice by phone enhances use of infliximab biosimilars
van Eijk SC, Arndt LK, Neitemeier S[Volltext]
Meeting Abstract
(18gaa05)
[Volltext]
Data quality of pharmaceutical claims data – How to measure, assess and improve?
Heck N, Jacke C[Volltext]
Meeting Abstract
(18gaa06)
[Volltext]
Agranulocytosis attributed to metamizole: an analysis of spontaneous reports in EudraVigilance 1985–2017
Hoffmann F, Bantel C, Jobski K[Volltext]
Meeting Abstract
(18gaa07)
[Volltext]
Real-world treatment persistence and associated costs with biologic therapy in patients with inflammatory bowel disease (IBD): Results of a retrospective cohort analysis of 1,248 patients treated in Germany
Wilke T, Gottschalk F, Groth A, Brandes A, Ratsch B, Fuchs A, Deiters B, Bokemeyer B[Volltext]
Meeting Abstract
(18gaa09)
[Volltext]
Contaminated valsartan: how were patients affected
Selke GW, Schüssel K, Langner I, Eichler U[Volltext]
Meeting Abstract
(18gaa10)
[Volltext]
Patients with polypharmacy: How many physicians and pharmacies are involved?
Lappe V, Ihle P, Schubert I, Grandt D[Volltext]
Meeting Abstract
(18gaa11)
[Volltext]
Benefit of a clinical pharmacist on a German surgical intensive care unit – A controlled interventional study
Kessemeier N, Meyn D, Höckel M, Reitze J, Culmsee C, Tryba M[Volltext]
Meeting Abstract
(18gaa12)
[Volltext]
Two years’ experience of using morbidity related groups (MRG) for economic evaluation of drug prescriptions in outpatient care in Schleswig-Holstein
Schuster R, Heidbreder M, Emcke T[Volltext]
Meeting Abstract
(18gaa13)
[Volltext]
A hospital standard on “Good Practice in Prescribing Medicines” – a quality parameter and set of minimum requirements for computerised physician order entry (CPOE) systems
Vogt W, Buchelt M, Hanel A, Eberlein-Gonska M, Knoth H[Volltext]
Meeting Abstract
(18gaa14)
[Volltext]
Medication Analysis for Hospital Patients with Renal Insufficiency: from project development to service establishment
Kastner B, Speckner W, Albrecht J[Volltext]
Meeting Abstract
(18gaa15)
[Volltext]
Development of a deprescribing guideline for the COFRAIL study: Family conferences and shared prioritisation to improve patient safety in the frail elderly. A cluster randomised intervention trial in primary care
Mann NK, Schmiedl S, Altiner A, Icks A, Meyer G, Mortsiefer A, Wiese B, Wilm S, Thürmann PA[Volltext]
Meeting Abstract
(18gaa16)
[Volltext]
Hospital pharmacy aspects of discharge management in Baden-Wuerttemberg hospitals – survey results 2017 and future perspectives
von Ameln-Mayerhofer A, Weissbarth A, Ausschuss Krankenhauspharmazie[Volltext]
Meeting Abstract
(18gaa17)
[Volltext]
A survey among health care professionals regarding electronic health record systems
Neininger MP, Bellstedt LM, Bertsche T[Volltext]
Meeting Abstract
(18gaa18)
[Volltext]
Using failure mode and effects analysis to increase patients’ safety in chemotherapy
Weber L, Schulze I, Jaehde U[Volltext]
Meeting Abstract
(18gaa19)
[Volltext]
Influence of metabolic profiles on drug safety in routine care in Germany – the EMPAR project
Huebner T, Steffens M, Fracowiak J, Gomm W, Roethlein C, Garling M, Langner D, Linder R, Haenisch B, Stingl J[Volltext]
Meeting Abstract
(18gaa20)
[Volltext]
Antiepileptic drug use and dementia risk – analyses of Finnish Health Register and German Health Insurance data
Taipale H, Gomm W, Broich K, Maier W, Tolppanen AM, Tanskanen A, Tiihonen J, Hartikainen S, Haenisch B[Volltext]
Meeting Abstract
(18gaa21)
[Volltext]
The most frequently reported adverse drug reactions and suspected drugs – descriptive analysis of spontaneous reports contained in the adverse drug reaction database of the Federal Institute for Drugs and Medical Devices in Germany (1978–2016)
Dubrall D, Schmid M, Alešik E, Paeschke N, Stingl J, Sachs B[Volltext]
